In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Opko Health, with a price target of $3.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors including the strategic moves and future prospects of Opko Health. Despite a decline in total revenue for the second quarter of 2025, the company has updated its full-year guidance, projecting total revenue between $640-660 million. This includes anticipated revenue from divested oncology assets and other revenue streams, which suggests a potential for recovery and growth.
Additionally, the impending closure of the Labcorp transaction is expected to enhance Opko’s financial position. This deal involves the sale of certain laboratory testing businesses, which could streamline operations and improve cash flow. Furthermore, Opko’s subsidiary, ModeX, is advancing its pipeline with promising developments in immuno-oncology, including a Phase 1 trial for a tetraspecific antibody targeting solid tumors. These strategic initiatives and potential future gains underpin Yi Chen’s optimistic outlook and Buy rating for Opko Health.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $3.00 price target.